RHOT1

Across TCGA pan-cancer cohorts, RHOT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RHOT1 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RHOT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RHOT1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where RHOT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	30	view →
HNSC	DFS	Median	All	0.303	0.886	.007	24	view →
LSCC	DFS	Quartile	All	0.276	1.000	.004	7	view →
GBM	DFS	Quartile	All	0.854	0.587	.006	3	view →
LUAD	OS	Tertile	II,III,IV	0.750	0.473	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RHOT1–CCRCC (DFS)

Open the CCRCC breakdown →